Tumefactive demyelination presenting during bevacizumab treatment

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Case Rep
Hauptverfasser: Rice, Claire M, Rossiter, David, Fehmi, Janev, Stevens, James C, Renowden, Shelley A, Cohen, Nicki, Bailey, Clare, Scolding, Neil J
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4691864/
https://ncbi.nlm.nih.gov/pubmed/26677151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2015-212173
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge